Conflict of interest None
The skin-blanching assay
Article first published online: 4 FEB 2012
© 2012 The Authors. Journal of the European Academy of Dermatology and Venereology © 2012 European Academy of Dermatology and Venereology
Journal of the European Academy of Dermatology and Venereology
Volume 26, Issue 10, pages 1197–1202, October 2012
How to Cite
Smit, P., Neumann, H.A.M. and Thio, H.B. (2012), The skin-blanching assay. Journal of the European Academy of Dermatology and Venereology, 26: 1197–1202. doi: 10.1111/j.1468-3083.2012.04449.x
Funding sources None.
- Issue published online: 10 SEP 2012
- Article first published online: 4 FEB 2012
- Received: 10 May 2011; Accepted: 12 January 2012
The skin-blanching assay is used for the determination and bioequivalence of dermatologic glucocorticoids (GCs). The exact mechanism of the production of blanching is not fully understood, but it is considered that local vasoconstriction of the skin microvasculature and the consequent blood-flow reduction cause this phenomenon. Several factors influence skin blanching, including drug concentration, duration of application, nature of vehicle, occlusion, posture and location. The intensity of vasoconstriction can be measured in several ways: visual or quantitative methods, such as reflectance spectroscopy, thermography, laser Doppler velocimetry and chromametry. In literature, contradicting results in the correlation of the skin-blanching assay with different tests to determine GC sensitivity have been reported, limiting its clinical usefulness.